ReviewDiagnostics (Basel, Switzerland)2021
Cardiac Exosomes in Ischemic Heart Disease- A Narrative Review.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Exosomes Enhance Diagnosis and Therapy of Ischemic Heart Disease: Insights and Advances.Journal of cardiovascular translational research · 2026Review
- Beneficial and challenges of exosome application in ischemic heart disease.Stem cell research & therapy · 2025Review
- Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.Military Medical Research · 2025Review
- Mitochondrial transplantation for cardioprotection and induction of angiogenesis in ischemic heart disease.Stem cell research & therapy · 2025Review
- Identification of an anti-inflammatory action of exosome release in P2YFrontiers in pharmacology · 2025Article
- A double-edged effect of hypoxia on astrocyte-derived exosome releases.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Exosomes in Atherosclerosis: Role in the Pathogenesis and Targets for Therapy.Current medicinal chemistry · 2025Review
- The Role of QRS Complex and ST-Segment in Major Adverse Cardiovascular Events Prediction in Patients with ST Elevated Myocardial Infarction: A 6-Year Follow-Up Study.Diagnostics (Basel, Switzerland) · 2024Article
- Extracellular Vesicles and Ischemic Cardiovascular Diseases.Advances in experimental medicine and biology · 2023Article
- Molecular Docking and Intracellular Translocation of Extracellular Vesicles for Efficient Drug Delivery.International journal of molecular sciences · 2022Review
- Research Progress on Transorgan Regulation of the Cardiovascular and Motor System through Cardiogenic Exosomes.International journal of molecular sciences · 2022Review
- Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation: A Report From the National Heart, Lung, and Blood Institute and the National Institutes of Health Office of the Director Workshop.JACC. Basic to translational science · 2022Review
- New Developments in Exosomal lncRNAs in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2021Review
- Exosomes and Exosomal Non-coding RNAs Are Novel Promises for the Mechanism-Based Diagnosis and Treatments of Atrial Fibrillation.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Ischemic heart disease (IHD) is the primary cause of death globally. IHD is associated with the disruption of blood supply to the heart muscles, which often results in myocardial infarction (MI) that further may progress to heart failure (HF). Exosomes are a subgroup of extracellular vesicles that can be secreted by virtually all types of cells, including cardiomyocytes, cardiac fibroblasts, endothelial cells, and stem and progenitor cells. Exosomes represent an important means of cell-cell communication through the transport of proteins, coding and non-coding RNA, and other bioactive molecules. Several studies show that exosomes play an important role in the progression of IHD, including endothelial dysfunction, the development of arterial atherosclerosis, ischemic reperfusion injury, and HF development. Recently, promising data have been shown that designates exosomes as carriers of cardioprotective molecules that enhance the survival of recipient cells undergoing ischemia. In this review, we summarize the functional involvement of exosomes regarding IHD. We also highlight the cardioprotective effects of native and bioengineered exosomes to IHD, as well as the possibility of using exosomes as natural biomarkers of cardiovascular diseases. Lastly, we discuss the opportunities and challenges that need to be addressed before exosomes can be used in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.